Mounjaro vs Ozempic

Mounjaro For Weight Loss vs Ozempic for Weight Loss

 

At My Concierge MD, We think a medical practitioner should choose between Mounjaro and Ozempic after carefully assessing the patient’s medical history, present health, and specific requirements. Every prescription has a unique set of potential side effects and drug interactions that must also be taken into account.

Mounjaro is mostly used to treat excessive blood pressure and heart failure. It works by relaxing blood vessels and lowering the workload on the heart. Ozempic, on the other hand, is used to treat type 2 diabetes by imitating a hormone that helps regulate blood sugar levels.

Both Mounjaro and Ozempic are well-known diabetes medicines. Metformin and canagliflozin are both ingredients in the combo medication Mounjaro. It functions by lowering blood glucose levels and assisting patients in losing body weight. On the other hand, semaglutide is a component of the injectable medication Ozempic. It increases the body’s production of the hormone insulin, which lowers blood sugar levels.

Although both diabetes medications have advantages, research suggests that Ozempic may be preferable to Mounjaro in terms of lowering HbA1c levels. Mounjaro works as a better solution for persons who struggle with weight management.

Obesity and diabetes are becoming increasingly common worldwide, particularly in industrialized countries, and are referred to as the “twin epidemics.” As a result, advanced therapeutic methods are required. Tirzepatide, also known as a ‘twincretin,’ is the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist that can significantly lower glycemic levels and improve insulin sensitivity, as well as reduce body weight by more than 20% and improve lipid metabolism. This innovative anti-diabetic medicine is a synthetic peptide analog of the human GIP hormone with a C20 fatty-diacid component added that, using acylation technology, may bind to albumin to provide a once-week dose of the drug by subcutaneous injection.

Online Prescription for Ozempic or Mounjaro in Los Angeles

Contact us at 310-299-8959 to schedule an in office consult or virtual consult

or Book Online to receive your prescription of Ozempic, Mounjaro or other Semaglutide or Tirzepatide for weight loss.

• Virtual Consult with MD & Nutritionist $450
• 3 Month Supply of the best compounded semaglutide injection  $750 ( Special Pricing) 
• Follow Ups $200
• Lose 10 – 20% of body fat safely and effectively

 

Are Ozempic and Mounjaro the same?

While both medications are used to treat type 2 diabetes, their active components and mechanisms of action differ. Ozempic is a brand name for semaglutide, a glucagon-like peptide 1 or GLP 1 receptor agonist that helps regulate blood sugar by increasing insulin secretion while reducing glucagon production. On the other hand, Mounjaro is a brand name for empagliflozin, is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that limits glucose reabsorption in the kidneys, resulting in increased urine glucose excretion and improved control of glycemic levels. Both prescription drugs have possible side effects and may not be appropriate for everyone.

As a result, when taking Type 2 diabetes medication, following your healthcare provider‘s assistance and continually monitoring your blood sugar levels is essential.

What are the similarities between Mounjaro and Ozempic?

While both weight loss medications have proven to be effective in managing blood sugar levels, it is important to note that they have different mechanisms of action and potential side effects.

Similarities

• Both are weight loss drugs used to treat diabetes and assist lower blood sugar levels.
• They both function by raising insulin synthesis in the body through distinct processes.
• Both medicines may cause nausea, vomiting, and diarrhea.
• They are both prescription drugs that must be administered under the supervision of a physician.
• Because both medications may interact with other drugs, it is critical to advise your doctor of any other medications you are taking.
• In clinical trials, both have been proven to be beneficial in decreasing HbA1c levels.

Mounjaro is a once-daily injection containing the active component albiglutide, while Ozempic is a once-weekly injection.

The new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist MounjaroTM (tirzepatide) injection from Eli Lilly and Company (NYSE: LLY) has been given FDA approval. It is indicated as a supplement to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro is not recommended for usage in people with type 1 diabetes mellitus and has not been evaluated in patients with a history of pancreatitis.

What are the side effects of Mounjaro and Ozempic?

Both Ozempic and Mounjaro have potential adverse effects, though individuals may experience them differently.

The most common side effects of Mounjaro may include:

• Urinary tract infections
• Headache
• Nausea
• Diarrhea
• Vomiting

The side effects of Ozempic may include:

• Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation, abdominal pain) 5% to 6% (vs. 4% on placebo)
• Headache
• Hypoglycemia (low blood sugar)
• Injection site reactions (such as redness, swelling, or itching at the injection site)
• Thyroid tumors (rare)

According to U.S. Food And Drug Administration, Mounjaro induces thyroid C-cell tumors in rats. It is unknown if Mounjaro contributes to the development of such malignancies, particularly medullary thyroid carcinoma, in people. Patients with Multiple Endocrine Neoplasia syndrome type 2, or a personal or family history of medullary thyroid cancer shouldn’t take Mounjaro.

Mounjaro is not recommended for use in people with type 1 diabetes and has not been investigated in patients who have had a history of inflammation in their pancreas (pancreatitis).

How do Mounjaro and Ozempic compare in terms of dosing?

Although both diabetes drugs can be injected, their dose requirements are different.

Mounjaro

Mounjaro‘s beginning dose is 2.5 mg administered subcutaneously once per week; after 4 weeks, the amount is increased to 5 mg once per week. The 2.5 mg dosage is for treatment beginning only; glycemic control is not the goal. After at least 4 weeks, if further glycemic control is required, your doctor might give you a much higher dose. The highest dose is 15 mg, administered subcutaneously once per week.

At 40 weeks (total effect), the difference in mean SBP change from baseline between the tirzepatide and comparator groups ranged from 1.3 to 5.1 mmHg dose of Mounjaro(tirzepatide) 5 mg, 1.7 to 6.5 mmHg for tirzepatide 10 mg, and 3.1 to 11.5 mmHg for tirzepatide 15 mg. With varying degrees of contributions from weight-loss-independent effects throughout the various studies, these SBP decreases were predominantly mediated by significant weight loss. The difference in SBP change between the tirzepatide and insulin glargine groups in the SURPASS-4 research, which included patients with established cardiovascular disease, was explained by weight reduction effects in 33% to 57% of cases.

Ozempic

Ozempic is a medication used for glycemic control, and its starting dose is 0.25 mg, which is administered subcutaneously once a week. However, it’s important to note that this dose is not effective for controlling glycemic levels, and is only intended to initiate treatment. After 4 weeks, the dosage is increased to 0.5 mg once weekly. If additional glycemic control is needed, your doctor may further adjust your dosage after at least 4 weeks. It’s crucial not to exceed a maximum weekly dose of 2 mg for Ozempic.

The effectiveness and safety of semaglutide have been evaluated with placebo and other pharmacologic treatments for diabetes (PTD) in nine phase 3, multicenter SUSTAIN studies. In these studies, semaglutide produced weight loss of around 4.5 kg and a hemoglobin A1c (HbA1c) reduction of approximately 1.5%, which was equivalent to dulaglutide’s HbA1c reduction of approximately 1.5%. Additionally, semaglutide has been shown to significantly reduce the chance of dying from cardiovascular events, having a nonfatal myocardial infarction, or having a nonfatal heart attack (hazard ratio: 0.74; 95% confidence interval: 0.58–0.95). A link between semaglutide medication and an elevated risk of retinal problems in patients with preexisting diabetic retinopathy was identified as a safety finding from the Cardiovascular outcomes trial.

Mounjaro and ozempic injection near me

My Concierge, MD, Beverly Hills, offers the best Mounjaro and ozempic injections near me in Beverly Hills but can also come to your home or office throughout the Los Angeles area. We serve patients near Beverly Hills, Bel Air, West Hollywood, Santa Monica, West Los Angeles, Culver City, Hollywood, Venice, Marina del Rey, Malibu, Manhattan Beach, Redondo Beach, Downtown Los Angeles, Encino, Woodland Hills, Sherman Oaks, Calabasas, Burbank, Glendale, Hidden Hills, Agoura Hills, Northridge, North Hollywood, Topanga, Canoga Park, Reseda, Valley Glen, Chatsworth, West Hills, Winnetka, Universal City, Silverlake, Echo Park, and many more.

References

1. Chavda VP, Jinal Ajabiya, Teli DM, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. 2022;27(13):4315-4315. doi:https://doi.org/10.3390/molecules27134315

2. FDA approves Lilly’s MounjaroTM (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes | Eli Lilly and Company. Eli Lilly and Company. Published 2022. Accessed June 25, 2023. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and

3. Office. FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes. U.S. Food and Drug Administration. Published 2022. Accessed June 25, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes

4. Ildiko Lingvay, Ofri Mosenzon, Brown K, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. 2023;22(1). doi:https://doi.org/10.1186/s12933-023-01797-5

5. Miles KE, Kerr JA. Semaglutide for the Treatment of Type 2 Diabetes Mellitus. 2018;34(6):281-289. doi:https://doi.org/10.1177/8755122518790925